Cantor Fitzgerald reiterated an Overweight rating and $21.00 price target on Cytokinetics (NASDAQ: CYTK). 4Q16 fully diluted EPS was $0.16 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

FBR Capital Reiterates Outperform on Cytokinetics (CYTK) Following 4Q February 17, 2017 7:17 AM Cytokinetics (CYTK): Transformative VITALITY-ALS Readout on Track - NeedhamFebruary 17, 2017 6:58 AM Piper Jaffray Reiterates Overweight Rating and $15 PT on Cytokinetics (CYTK) Following 4Q16 ResultsFebruary 17, 2017 6:05 AM After-Hours Stock Movers 02/16:: (RSGE) (TRUE) (CYTK) Higher; (NUS) (PI) (FLS) Lower (more...)February 16, 2017 6:05 PM Cytokinetics (CYTK) Tops Q4 EPS by 43cFebruary 16, 2017 4:06 PM Cytokinetics, Inc. Reports Fourth Quarter 2016 Financial ResultsFebruary 16, 2017 4:00 PM